Organic Active Ingredients TRIZ Cases

A foam aerosol with lipophilic enhancers improves minoxidil skin permeation while preventing scalp run-off during hair loss treatment.

A solid dispersion of Compound I with copovidone and crystalline sofosbuvir improves bioavailability while reducing food-effect and dosing variability.

A novel CRBN ligand scaffold enables PROTAC formation with high activation rates while reducing neutropenia, thrombocytopenia, and neuropathy.

Quinazolin-8-yl derivatives inhibit EGFR kinase, helping treat EGFR-mutant cancers by modulating cellular proliferation and differentiation.

A 5-40 μL coated valve cuts propellant release and albuterol sticking, improving dose consistency in a smaller inhaler.

Twice-daily PDE4B inhibitor plus pirfenidone or nintedanib slows PF-ILD progression while reducing gastrointestinal adverse events.

HLSC-derived extracellular vesicles deliver miR222 to suppress miR21, TGFβ, and collagen production in hyperglycemia-driven renal fibrosis.

Segmented azaketolide synthesis cuts macrolide route complexity while retaining potent activity against resistant Gram-negative bacteria.

Blocking the C5aR1 complement pathway helps prevent or treat taxane hypersensitivity reactions that persist despite standard premedication.

Controlled mismatches, bulges, and loops shape an ADAR editing substrate that improves target RNA editing efficiency and specificity.

Citrate-to-Tris buffer exchange helps nucleic acid lipid nanoparticles balance delivery efficiency, storage stability, and lower cytotoxicity.

A wax-polymer-sugar zonisamide formulation delivers pseudo zero-order release within short animal GI transit, avoiding burst release and poor bioavailability.

WRN helicase inhibition exploits dMMR synthetic lethality to trigger DNA breaks and apoptosis in MSI-H tumors with resistance to current therapies.

Continuous NO release combined with PDE4 inhibition improves microcirculation, reduces inflammation, and broadens ARDS treatment.

Modified dsRNA and lipid carriers suppress CIDEB mRNA while improving in vivo delivery and stability for NAFLD and NASH treatment.

Selective pyrimidine EGFR inhibitors broaden treatment coverage to exon 20 insertions while improving safety and activity against resistant mutants.

Segmented heterocyclic scaffold tuning improves AAK1 inhibition while preserving compound diversity for CNS disease drug discovery.

Controlled benzoate dosing reduces microglia activation and neuroinflammation to improve long COVID brain fog without adverse side effects.

A macrocyclic compound targets the TYK2 JH2 domain to improve selectivity over JAK family members while enabling blood-brain barrier penetration.

Defined spiro compound crystal forms use XRPD fingerprints to improve stability, factor D inhibition, and oral bioavailability.

Specific tetracycline analogs improve mPTP-opening inhibition while addressing the limits of cyclosporine A in physicochemical properties and therapy.

Novel dispiropyrrolidine derivatives block Mdm2-p53 binding to restore p53 activity and suppress cancer cell proliferation.

Combining an anxiolytic with a stimulant helps treat PTSD and HSDD while simplifying administration and sustaining symptom relief.

PPEF2 genotyping guides iloperidone selection and dosing to reduce schizophrenia treatment trial and error and improve symptom control.

Tie-2 activation via HPTPβ/VE-PTP inhibition helps reduce vascular leak, inflammation, and edema while improving lung oxygenation in ARDS.

An elastic linear member lets the gastrostomy catheter bumper deform for easier insertion while maintaining stable long-term placement.

Cas13b guide RNA delivered by AAV silences DUX4 RNA to reduce muscle toxicity and support cell survival in FSHD.

Targeting coronavirus papain-like protease with YM155, tanshinone I, and cryptotanshinone enables antiviral activity with low cytotoxicity.

A multi-gene expression signature improves recurrence risk prediction in early-stage breast cancer, helping avoid overtreatment and toxicity.

Targeted dsRNA silences ANGPTL3 expression to lower serum lipids and address inconsistent response to conventional lipid therapies.

Combining a CB1 antagonist with everolimus helps suppress neuroendocrine tumor growth while preventing resistance pathways in metastatic NENs.

Synthetic apoptosis-mimicking scaffold structures recruit macrophages and endogenous stem cells to regenerate bone without cell seeding.

Reversible copper-ligand self-assembly controls degradation and maintains copper ion release over 1 to 30 days for antimicrobial use.

Simplified acyl hydrazide linkers preserve nanomolar LecA binding while improving synthesis and drug-like properties for blocking P. aeruginosa biofilms.

Crystalline forms of a TYK2 inhibitor improve selectivity, potency, and pharmacokinetic behavior for autoimmune disease treatment.

Combining an EP4 antagonist with immune checkpoint inhibitors blocks PGE2-driven immune suppression and improves antitumor response.

Converting psilocin into pharmaceutically acceptable salts improves crystallinity, purity, oxidation stability, and water solubility.

Amorphous solid dispersions with polymers raise PARP inhibitor dissolution and oral bioavailability while limiting crystalline content.

A polymer-based dasatinib amorphous solid dispersion maintains delivery despite elevated gastric pH and acid-reducing agents.

Targeting VDAC1 blocks mtDNA release to curb IBD inflammation while avoiding the broad immune suppression seen with current treatments.

Superparamagnetic neutrophil-mimetic vesicles improve tumor targeting, reduce harm to normal cells, and enhance anticancer drug delivery.

A biodegradable subcutaneous implant releases hydrocortisone continuously to restore circadian cortisol levels and avoid frequent dosing.

A SERM and pregnenolone combination raises testosterone while maintaining LH and FSH to preserve testicular function and fertility.

Specific bupropion and dextromethorphan dosing helps treat depression and Alzheimer's agitation while limiting QT prolongation and dissociation.

Specific polymorphs of an EGFR inhibitor improve brain penetrance and stability, addressing glioblastoma resistance and delivery limits.

Twice-weekly intravenous brincidofovir dosing defines a clearer regimen to cut adenovirus viral load faster and reduce treatment failure.

Structural changes to itraconazole reduce CYP3A4 inhibition while preserving anti-angiogenic and Hedgehog pathway activity for cancer treatment.

Local pazopanib delivery raises neutrophil ROS to reduce lung permeability, edema, and mortality in acute lung injury.

Electrophilic thiophene derivatives selectively covalently bind KRAS G12C to improve antiproliferative activity while limiting off-target toxicity.

C4-modified oleanolic acid derivatives selectively reduce IL-17 levels to improve autoimmune disease treatment with fewer side effects.

Targeted siRNA compositions silence INHBE in hepatocytes to address obesity and metabolic disease while balancing efficacy with sequence complexity.

A low-dose intravenous flurbiprofen axetil emulsion extends fever relief to 6-10 hours while reducing adverse reactions and dosing frequency.

Nanofiltration and water solvent crystallization recover high-purity mevalonate salts from aqueous broth without organic solvents or complex extraction.

Novel scaffold variants modulate YAP/TEAD binding to suppress target genes while balancing anticancer efficacy, toxicity, and synthesis complexity.

Combining undenatured Type II collagen with probiotic cell matter and prebiotics improves joint repair by modulating cytokines and reducing inflammation.

Anti-transferrin receptor siRNA conjugates improve cellular uptake and blood stability while reducing DMPK mRNA and immune stimulation in DM1.

Hairpin RNA delivered by AAV lowers alpha-synuclein transcripts to therapeutic levels while limiting synaptic safety risks and off-target effects.

A prefilled single-use autoinjector delivers low-concentration ergoline quickly, improving migraine treatment access while reducing side effects.

Stable amide linkages replace hydrolysis-prone amidine bonds to improve mannose retention, consistency, and shelf-life in mannosylated dextrans.

A dihydroberberine and ergothioneine combination reduces AGEs by scavenging ROS and boosting antioxidant enzymes with fewer safety concerns.

A sub-coat plus pH-responsive enteric layer protects a BTK inhibitor from stomach exposure, improving intestinal absorption and drug consistency.

A bioactive glass and hyaluronic acid lotion delivers carbidopa/levodopa through skin to bypass dysphagia and GI dysfunction.

Engineered retro-AAV capsids and D1-MSN regulatory elements enable selective retrograde gene delivery to restore Parkinsonian motor circuits.

Pharmacological chaperones stabilize GCase to extend activity in brain cells, reducing infusion burden and addressing neurological Gaucher and Parkinson's disease.

Targets budesonide release to the distal ileum to lower pathogenic IgA antibodies in IgA nephropathy while limiting systemic side effects.

Chemically linked guide RNA-Cas RNPs improve targeted delivery, reduce off-target editing and host immunity, and help clear latent viral genomes.

Mutation-specific KRAS G12C compounds improve treatment efficacy in pancreatic, colorectal, and lung cancers that resist existing therapies.

A hypertonic intratympanic composition boosts round-window retention of anti-platinum chemoprotectant to reduce chemotherapy-related hearing loss.

AAV9-delivered cBIN1 restores calcium handling and mitochondrial function to slow diabetic cardiomyopathy progression and aid HFpEF.

Sublingual JAK inhibitor films treat autoimmune hair loss through oral mucosal absorption, avoiding oily topical residue and swallowing barriers.

Targeting Claudin-3 with siRNA or antibodies reduces bile acid buildup, ameliorates cholestatic liver injury, and helps prevent fibrosis.

Combining hesperidin, quercetin, rutin, and optional additives improves viral protein binding and helps treat coronavirus, influenza, and rhinovirus infections.

Combining glaucoma and post-op eye medications in one ophthalmic composition improves compliance, lowers cost, and reduces preservative exposure.

Erythritol-based phenylbutyrate esters improve bioavailability and residence time, extending therapeutic reach beyond glycerol esters.

Exosome-delivered miRNAs suppress HMGB1 expression to reduce inflammation in acute lung injury, ARDS, and sepsis.

Selective A2a/A2b antagonist scaffolds block adenosine-driven tumor immunosuppression and can improve anti-tumor response with PD-1 therapy.

Absorbent nasal plugs with airflow tunnels and retrieval features extend mucosal contact time for localized drug delivery while limiting evaporation loss.

Adding low-level HPMC to hyaluronic acid MSC hydrogels improves cell viability while preserving therapeutic potential for lupus and kidney fibrosis.

Mutation-specific compounds bind Asp12 in KRAS G12D and hold the inactive GDP-bound state to block cancer signaling.

Prodrug glucuronide and sulfate conjugates improve oral bioavailability and sustain plasma exposure to reduce peak-related fluctuations in Parkinson's treatment.

Cariprazine embonate crystal forms balance solubility and stability to enable sustained-release formulations with less frequent dosing.

Novel NHE3 inhibitor compounds improve selective intestinal sodium and phosphate reduction to help manage CKD, CVD, and bone disease.

A hyaluronic acid and hypromellose sheet stabilizes green tea catechins while maintaining oral mucosal adhesion and durability.

Crystalline forms I and IIIA reduce hygroscopicity and photodegradation in a benzothiazole MEK inhibitor while improving storage stability and purity.

Small-molecule GLP1R agonists use tuned imidazole-benzo[d][1,3]dioxole structures to improve ADME while treating obesity and type 2 diabetes.

Binding intron 1B of TAU pre-mRNA shifts splicing to increase exon 1B-containing mRNA and lower TAU protein expression for TAU-related disease.

Selective amino triazolopyrimidine and triazolopyrazine antagonists block A2A/A2B signaling to boost anti-tumor T-cell responses with fewer off-target effects.

Novel EP300/CBP inhibitor compounds use modular heterocyclic substitutions to improve selectivity and inhibitory activity against tumor cells.

Strategic altritol placement in dsRNA improves nuclease stability while preserving RNAi activity and reducing off-target effects.

Fluorinated αv integrin antagonists enable topical retinal delivery, avoiding invasive injections while inhibiting angiogenesis in AMD, DR, and DME.

By reducing RTEL1 expression with antisense oligonucleotides or siRNA, this case shows a route to destabilize HBV cccDNA and shorten treatment.

By activating AMPK and scavenging ROS, DHB helps preserve red blood cell deformability and endurance during exercise.

A modified Kex cleavage site and non-MIS leader sequence improve recombinant MIS cleavage, yield, and bioactivity for MISRII-targeted therapy.

New GnRH antagonist crystal forms improve solubility and resist moisture uptake, easing pharmaceutical production, storage, and scale-up.

Defined crystalline tryptamine salts use XRPD characterization to fix molecular weight errors and improve dosing accuracy in pharmaceutical formulations.

MSR1-targeting antibodies deliver LXR agonists, steroids, or rifamycins to receptor-expressing cells to improve specificity and bioavailability.

Low- or no-sodium peritoneal infusates create osmotic and diffusion gradients to remove sodium overload while stabilizing serum sodium.

Aryl ether-substituted heterocycles improve oral GLP1R agonist exposure and half-life while avoiding injection-dependent treatment.

AAV delivery with an RGC-specific promoter enables CRISPR knockdown of CHOP and SARM1 to protect retinal ganglion cells in optic neuropathy.

Compound A drives selective polyQ-AR degradation through the ubiquitin-proteasome system to ease SBMA muscle weakness and motor decline.

AFSC-derived extracellular vesicles restore VEGF signaling, delay renal fibrosis, and support kidney function in Alport Syndrome.

Phosphorothioate cyclic dinucleotides and cleavable antibody linkers support stable, broad STING activation and targeted release.

Targeted pyridine and ribose substitutions raise cellular NAD+ while improving absorption and stability in mammalian cells.

Novel substituted CGRP antagonists vary ring and linker structures to broaden therapeutic options across migraine-related disorders.

Immortalized corneal stromal stem cells provide defined exosomes that reduce scars and avoid surgical corneal transplantation.

This case uses discrete reaction steps and protecting groups to improve synthesis precision for PD-1/PD-L1 inhibitor salts.

This case uses controlled crystallization and azetidine substitution to improve KRAS G12C inhibitor stability and solubility.

This case uses four BSA-based dose ranges for mirdametinib to balance NF1-PN response with manageable adverse effects.

This formulation uses HAT antioxidants, pH control, and co-solvents to protect nicardipine during production and storage.

3D stem-cell spheroids address inefficient vesicle production by enhancing angiogenic factors.

Low-molecular-weight HPMC extends nicotinamide release toward the colon.

This case examines formula-based compounds that inhibit estrogen receptor alpha and may reduce tumor volume in breast cancer.

TGF-β2 antisense agents combine with checkpoint inhibitors and interleukins to broaden response while limiting toxicity.

Receptor-mediated uptake and endosomal release deliver DUX4-inhibiting oligonucleotides selectively to muscle cells for FSHD treatment.

Sphingolipid compounds target S1PR1 and S1PR4, limiting lymphocyte release and inflammation without cardiovascular side effects.

This case combines NAD+, American Ginseng, and PQQ with other micronutrients to inhibit IL-6 and support mitochondrial brain health.

A granulated excipient formulation enables conventional rotary presses to make palatable soft-chew tablets with consistent texture.

The derivative inhibits TNF-α or IL-6-induced monocyte adhesion for oral treatment of inflammatory bowel disease and rheumatoid arthritis.

This case develops orally exposed spiro compounds that inhibit ERK2, suppress tumor growth, and show good tolerance.

Drug-loaded polymer microparticles gel on the ocular surface, reducing frequent dosing while sustaining release for at least five days.

A polymer and anionic sulfate/sulfonate surfactant matrix enables zero-order ketamine release, reducing plasma peaks and sustaining therapeutic levels.

This case uses selective A3AR agonists to inhibit trigeminal nociceptors for migraine relief without tolerance.

Targeted bacteria ferment milk oligosaccharides to raise acetate and lactate, reduce pathogens, and support immune maturation.

This case uses 2C compounds with high 5-HT2A affinity to treat inflammation while keeping plasma levels below detection limits.

A stabilized antiseptic formulation prevents precipitation of tint, polymer, and antiseptic components while supporting drape adhesion.

This case uses optimized small molecules to inhibit Cbl-b and enhance immune function for cancer and autoimmune disorders.

Step-up dosing combines an FcRH5/CD3 antibody with lenalidomide for high-risk myeloma.

A high-capacity CAV-2 vector targets neurons with SCN1A, addressing limited vector capacity and weak neuronal delivery.

This case uses a FAAH inhibitor to address PTSD hyperarousal and startle symptoms through endocannabinoid modulation.

This beverage combines hydrogen water and amino acids to sustain nitric oxide, supporting blood flow and endothelial health.

Genome-scale CRISPR screening and orthogonal validation reveal host gene targets for reducing SARS-CoV-2 infection.

See how phenolic and hydroxy-cinnamic acid acylation stabilizes a bright red anthocyanin colorant for beverages and foods.

Hydrolyzing organic acids before formulation improves monomer control and stability in aerosol precursor compositions.

This ADC approach targets EGFR-expressing cells and uses lysosomal cleavage to release Bcl-xL inhibitors while limiting systemic exposure.

Micronization, ethylene oxide sterilization, and 30% to 40% relative humidity help prevent clumping and improve artesunate dosing accuracy.

This case uses zinc-binding groups and localized molecular design to improve HDAC6 potency, selectivity, stability, and reduce toxicity.

This case uses Ser327/Ser339 vimentin substitutions and shRNA to reduce cancer-cell migration, invasion, and metastasis.

Substituted benzoannulene derivatives act as ERα antagonists and degraders to address resistance to conventional therapies.

This case uses spray-dried amorphous powder in a needle-free applicator to improve adrenaline stability and rapid nasal delivery.

This case uses periodic Azenosertib dosing to raise exposure while limiting toxicity in resistant tumors and combination therapy.

This case examines feed formulations using berberine alkaloids to prevent and treat infections while maintaining safe residue levels.

Obinutuzumab targets B-cells to reduce relapses and steroid toxicity in childhood INS.

This case uses creatinine clearance thresholds to guide ulotaront dosing and maintain safe metabolite exposure in renally impaired patients.

This case uses benzimidazolone small molecules to deliver GLP-1 activity orally while supporting insulin and glucagon regulation.

This case uses AAK1 inhibitors before or with chemotherapy to prevent neuropathy and preserve cancer treatment dosing.

This case combines RhoA and mTOR inhibitors to address membrane remodeling and primary cilia assembly defects in Lowe Syndrome.

This case grafts mouse CDRs onto human frameworks to retain receptor activity, support muscle growth, and reduce immunogenicity.

A valve communication path replaces chamber gas with liquid, supporting accurate dosing while reducing manual priming and tampering.

Polyoxyl 15-hydroxystearate micelles in propylene glycol support stable Plinabulin injection with high encapsulation efficiency.

This case develops substituted dioxino-pyridine compounds to improve IRAK-4 inhibition, stability, bioavailability, and tolerability.

Optimizing loss tangent and viscosity in a silicone adhesive suppresses cold flow, preserving the asenapine patch shape and handleability during storage.

Liposome encapsulation delivers peptide epitopes and oligonucleotides, resolving limited synthetic peptide efficacy while reducing side effects.

A hyperosmolar hyaluronic acid composition reduces corneal thickness through osmotic pressure.

Adjusting anti-CD30 antibody drug conjugate dosing schedules with granulopoiesis stimulating factors to reduce peripheral neuropathy and neutropenia severity.

Chemical compounds target signaling pathways to generate mature myotubes from myoblasts, resolving labor-intensive processes and genetic engineering complexity.

Polysorbate 20 in a vitamin B12 gel bridges oil and skin barriers, enabling deeper epidermal penetration that overcomes superficial distribution limits.

Hydrophilic microspheres precipitate hydrophobic drugs within their core, preventing burst release and enabling sustained therapeutic delivery.

Glyceryl behenate coating on quetiapine fumarate granules controls drug release rates through lubrication and barrier properties.

An oral complement factor D inhibitor maintains plasma concentrations to inhibit the alternative pathway.

Pyrazole carboxamide derivatives target trace amine associated receptor 1 while reducing adrenergic binding side effects.

Replacing monocarboxylic acids with dicarboxylic acids stabilizes the formulation against low-temperature precipitation and leakage.